our Premium Content: News alerts, weekly reports and conference planners

DRUG:

SLATE-KRAS

News alerts, weekly reports and conference planners

Company:

Gritstone bio

Drug class:

Immunostimulant, KRAS inhibitor

Related drugs:

anti-KRAS G12D mTCR PBL (0)

tirvalimogene teraplasmid (2)

Histone H3.3-K27M Neoantigen Vaccine Therapy (1)

AdHER2/neu DC Vaccine (0)

bioengineered allogeneic immune cells (0)

velimogene aliplasmid (0)

interferon alpha 2b (0)

dasiprotimut-T (0)

Bria-OTS (0)

CD25hi Treg depleted DLI (0)

recombinant human papillomavirus bivalent vaccine (0)

CodaLytic (0)

dendritic cell vaccine (0)

cancer vaccine MUC-1 (0)

autologous dendritic cell vaccine leaded with autologous tumor cell lysate (0)

DI Leu16 IL-2 (0)

DNAJB1-PRKACA peptide vaccine (0)

Dendritic cell renal cell carcinoma fusion vaccine (0)

FR Alpha Peptide Vaccine (0)

GVAX leukemia vaccine (0)

GVAX lung cancer vaccine (0)

types 6, 11, 16, 18 (0)

human papillomavirus 9-valent vaccine, recombinant (0)

H1299 cell lysate with iscomatrix adjuvant vaccine (0)

H1299 lung cancer cell lysate vaccine with Montanide ISA-51 VG adjuvant (0)

HER-2 pulsed DC1 (0)

HER2- and HER3-primed dendritic cells (0)

IDH1R132H peptide vaccine (0)

autologous γδ T lymphocytes (0)

MMP9FS (0)

KRAS peptide vaccine (0)

axalimogene filolisbac (0)

MVA-BN-Brachyury IV vaccine (0)

MVI-816 (0)

autologous dendritic cell vaccine (0)

NY-ESO-1 Iscomatrix (0)

NY-ESO-1 combined with MPLA vaccine (0)

Poly-ICLC matured DC adjuvanted NY-ESO-1/Melan-A-MART-1 peptide vaccine (0)

PolyPEPI 1018 (0)

rilimogene galvacirepvec (0)

live attenuated bacillus Calmette-Guerin (0)

Tri-Ad5 (0)

CMV-MVA vaccine (0)

UV1 (0)

Undisclosed VLP vaccine (0)

Undisclosed ovarian cancer vaccine (0)

alpha-tocopheroloxyacetic acid (0)

allogeneic K562-GM tumor cell vaccine (0)

allogeneic Myeloma GM-CSF Vaccine (0)

alpha-lactalbumin vaccine (0)

PG2 (0)

autologous Tcm cellular immunotherapy (0)

autologous formalin-fixed tumor vaccine (0)

mammaglobin-A DNA vaccine (0)

TG4010 (0)

STAT-401 (0)

multi-epitope melanoma peptide (0)

neoantigen DNA vaccine (0)

neoantigen peptide vaccine (0)

nonavalent HPV vaccine (0)

ADU-741 (0)

oral therapeutic vaccine V3-X (0)

p.DOM-WT1-126 DNA vaccine (0)

pING-hHER3FL (0)

polyvalent vaccine-KLH conjugate (0)

CDX-1401 (0)

CMN-001 (0)

self-amplifying RNA cancer vaccine (0)

anti-KRAS G12D mTCR PBL (0)

mRNA-5671 (0)

siG12D LODER (0)

›

A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens (GO-005) (NCT03953235)

Phase 1/2

Gritstone bio, Inc.

Completed

Phase 1/2

Gritstone bio, Inc.

Completed

Last update posted :

09/13/2023

Initiation :

07/18/2019

Primary completion :

03/10/2023

Completion :

03/10/2023

KRAS

KRAS G12C • KRAS G12D • KRAS G13D • KRAS G12 • NRAS Q61 • NRAS G12

Opdivo (nivolumab) • Yervoy (ipilimumab) • SLATE-KRAS

SLATE-KRAS

Trials

Trials